Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities

Wake Forest University Health Sciences (Other)
Overall Status
Recruiting ID
National Cancer Institute (NCI) (NIH)

Study Details

Study Description

Brief Summary

The purpose of this Phase 1 research study is to obtain data or information on the safety and effectiveness of the combination of gemcitabine, docetaxel with radiation.

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

Primary Objective:

• To determine the maximum tolerated doses Gemcitabine and Taxotere when given weekly with concurrent radiation in the neoadjuvant setting for patients with soft tissue sarcoma of the extremities.

Secondary Objective:

• To evaluate immunological changes induced by gemcitabine and docetaxel with radiation in patient with high risk-soft tissue sarcomas in blood. This would include T cell subsets, NK, and dendritic cells and tumor macrophages all of which make up the tumor microenvironment.

Long term follow-up will occur every 3-4 months for 24 months in person or video consultation.

Study Design

Study Type:
Anticipated Enrollment :
27 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
Phase I Trial Study of Gemcitabine and Docetaxel With Radiation in Adult Patients With High Grade and Greater Than 5 cm Soft Tissue Sarcoma of the Extremities
Actual Study Start Date :
Aug 18, 2020
Anticipated Primary Completion Date :
Aug 1, 2022
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Neoadjuvant Chemotherapy Plus Radiation Therapy

Up to 6 cycles (once a week) of chemotherapy with a 3+3 dose escalating plan (from 100 mg to 300 mg for Gemcitabine; 10 mg to 25 mg for Docetaxel) along with radiation (five days a week) for up to 6 weeks.

Drug: Gemcitabine
Gemcitabine will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity on a 3+3 escalating dose (100 mg/m² to 300 mg/m²)

Drug: Docetaxel
Docetaxel will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity (10 mg/m² to 25 mg/m²).
Other Names:
  • Taxotere
  • Radiation: Radiation
    Radiation is to be done with standard preop dose of 50 Gy but at lower doses per fraction. Thus 50.4 Gy in 28 FX. Radiation will be given for 5 days (Monday - Friday) every week for approx. 6 weeks.

    Procedure: Surgical Resection
    Upon completing neoadjuvant chemotherapy plus radiation therapy, surgical resection will occur.

    Other: Blood draws
    Before treatment, blood (about 2 tubes of 10 mls each) to better understand some aspects of participants' immune system before chemotherapy.

    Outcome Measures

    Primary Outcome Measures

    1. Maximum Tolerated Dose Chemotherapy and Radiation [Up to 8 weeks]

      Maximum tolerated dose of Gemcitabine and Taxotere and radiation will be completed by monitoring toxicities and using the 3+3 dose escalation plan.

    2. Number of Toxicity Incidences [8 weeks post-surgery]

      Complication/side effects from the chemotherapy combination of gemcitabine and taxotere concurrent with radiation will be assessed by toxicity counts/rates presented descriptively by toxicity, severity, and dose level using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Secondary Outcome Measures

    1. Number of Immunological Changes in Blood [4 years]

      The effects of the treatment on the immune system will be analyzed using paired t-test or the non-parametric counterpart. Correlations between immune cells and immune factor levels will be assessed using Spearman correlation coefficient. All tests will be two-sided with a significance level of 0.05, and no adjustment for multiple comparisons will be made due to the exploratory nature of these studies.

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    • Patients must have a histologically or cytologically confirmed Grade II or III soft tissue sarcoma that is considered to be resectable and are candidates for pre-op radiation.

    • Age greater than or equal to 18 years. No children will be enrolled on this protocol.

    • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.

    • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or double-barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

    • Ability to understand and the willingness to sign a written informed consent document.

    Exclusion Criteria:
    • Patients taking concurrent hormonal therapy, biologic or other chemotherapy are excluded except women on hormonal contraceptives.

    • Patients taking an investigational agent are excluded.

    • Pregnant and nursing women are excluded.

    • Patients who require amputation for local control.

    • Patients who underwent unplanned excision or other previous surgery involving the affected extremity.

    • Patients with sarcoma subtypes for which established chemotherapeutic regimens exist.

    • History of radiation to the limb.

    Contacts and Locations


    Site City State Country Postal Code
    1 Wake Forest Baptist Comprehensive Cancer Center Winston-Salem North Carolina United States 27157

    Sponsors and Collaborators

    • Wake Forest University Health Sciences
    • National Cancer Institute (NCI)


    • Principal Investigator: Shailaja Raj, MRCP, Wake Forest University Health Sciences

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    Wake Forest University Health Sciences Identifier:
    Other Study ID Numbers:
    • IRB00061621
    • P30CA012197
    • CCCWFU 71117
    First Posted:
    Jul 30, 2019
    Last Update Posted:
    Mar 8, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Plan to Share IPD:
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Product Manufactured in and Exported from the U.S.:
    Keywords provided by Wake Forest University Health Sciences
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 8, 2022